PROF Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
2.5M
-53.5%
5.3M
-10.7%
6.0M
+13.0%
5.3M
+139.2%
2.2M
Cost of Revenue
536.0K
-64.4%
1.5M
-24.2%
2.0M
+46.2%
1.4M
+129.0%
593.0K
Gross Profit
1.9M
-49.2%
3.8M
-4.0%
4.0M
+1.5%
3.9M
+143.0%
1.6M
Operating Expenses
13.0M
+9.8%
11.9M
+4.3%
11.4M
-11.6%
12.8M
-16.7%
15.4M
R&D
5.7M
+7.4%
5.3M
+23.2%
4.3M
-21.2%
5.4M
-11.2%
6.1M
SG&A
7.4M
+11.7%
6.6M
-7.0%
7.1M
-4.6%
7.4M
-20.4%
9.3M
Operating Income
-11066000
-38.0%
-8021000
-8.8%
-7369000
+17.3%
-8913000
+35.4%
-13806000
EBITDA
-10931000
-38.0%
-7921000
-9.1%
-7260000
+17.2%
-8766000
+35.9%
-13665000
Net Income
-9540000
-35.3%
-7053000
+13.7%
-8175000
-2.5%
-7977000
+49.2%
-15695000
EPS (Basic)
$-0.26
-36.8%
$-0.19
+29.6%
$-0.27
-3.8%
$-0.26
+50.0%
$-0.52
EPS (Diluted)
$-0.26
-36.8%
$-0.19
+29.6%
$-0.27
-3.8%
$-0.26
+50.0%
$-0.52
Shares (Diluted)
36.4M
+0.1%
36.3M
+18.1%
30.7M
+2.1%
30.1M
+0.2%
30.1M
Profound Medical (PROF) โ€” Financials